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The right to search for truth implies also a duty; one must not conceal any part of
what one has recognized to be true.
—Albert Einstein (inscribed on the base of the Albert Einstein memorial at the
National Academy of Sciences)
The success of the scientific enterprise requires first of all that scien-tists must embody honesty and integrity in every phase of their work.Without the uncompromising integrity of everyone involved in re-search, the entire edifice of science will eventually collapse, becauseeach new layer of knowledge is built on the accuracy and truth of theresearch that preceded it.
A great deal has been written in recent years on research integrity, fueled by such
highly publicized cases as those involving Thereza Imanishi-Kari and David Bal-
timore in Boston,1 Robert Gallo at the National Institutes of Health,2 and Francis
Collins at the Human Genome Project,3 each accused of transgressions against the
ethical and legal norms that guide research. Integrity in science means that the
investigators accept responsibility for all aspects of a study, from experimental
design through all stages of its execution, including publication. It implies that each
of these steps will be carried out with competence and honesty.
Integrity in research cannot be assured by law; it must come from the character
of those who carry out research. Nevertheless, medical journals have an important
role to play in reminding those who do research of their obligations to science. For
example, conflicts of interest arising from financial or other kinds of ties to
companies whose products are being studied may be a source of bias in reporting
research results. Journals have taken several different approaches to dealing with
these kinds of conflicts. Taking a firm position, The New England Journal of
Medicine in 1990 announced a policy in which they would refuse to publish any
article or editorial written by an employee of a company (or its competition) whose
product is important to the topic under discussion.4 Many protested that this policy
was overly zealous, akin to throwing out the baby with the bath water. For example,
under a policy of this kind, it has been pointed out, Thomas Edison could not have
published an article on the future of electricity.5
The Annals of Thoracic Surgery and The Journal of Thoracic and Cardiovas-
cular Surgery deal with such conflicts of interest by requiring that authors report any
financial conflict at the time of submission of their manuscripts. The editors may
then disclose such conflicts with the article, allowing readers to make their own
judgments about potential bias and possible effects on interpreting the research
results. Even a reasonable policy such as this still may be problematic. For example,
the term “conflict of interest” has pejorative connotations, so that even relatively
minor conflicts may result in reports being judged ad hominem, on the basis of
personal characteristics of their authors rather than strictly on their merits.5
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Yet another issue may directly affect integrity in the
reporting of research: control of research data and of deci-
sions to publish or not to publish by entities other than the
investigator; for example, industrial sponsors or institutions
such as universities. Industry now provides substantial sup-
port for research that often results in very good science with
important clinical implications. Yet, there have been several
instances in recent years when publication of research re-
sults was delayed or entirely blocked by companies that had
financially supported studies that produced results unfavor-
able to their products.6,7 Although we know of no published
examples of such problems in cardiothoracic surgery, the
large volume of industry-sponsored research in our field
suggests that they almost certainly exist. A recent survey of
academic life scientists found that nearly 20% of them
admitted that publication of their research results had been
significantly delayed (6 months or longer) for a variety of
reasons, including disputes over ownership of intellectual
property.8 Universities may demand similar delays in pub-
lication because of intellectual property issues. In one no-
torious recent case, a university supported an industrial
sponsor’s blockage of publication by one of its faculty
members. A clinical study produced unexpected negative
results for the company’s product, and when the physician-
researcher pursued publication anyway, the company’s at-
tempt to stop it (which eventually failed) was supported by
the university against its own faculty member. A series of
lawsuits resulted.9
In view of the disturbing trend of interference with
publication of research results, the International Committee
of Medical Journal Editors (ICMJE) has revised the “Uni-
form Requirements for Manuscripts Submitted to Biomed-
ical Journals: Writing and Editing for Biomedical Publica-
tion.” The new guideline is clear about the accountability of
scientists for their own research: “As the persons directly
responsible for their work, researchers therefore should not
enter into agreements that interfere with their access to the
data or their ability to analyze the data independently, to
prepare manuscripts, and to publish them.” The issue of
responsibilities of investigators vis-a`-vis sponsoring com-
panies was recently considered at some length in an edito-
rial that was published simultaneously in 12 medical jour-
nals in the fall of 2001.10 In their editorial, the group of
editors concluded that, because a manuscript is the intellec-
tual property of the research scientists rather than the spon-
sors of the study, “we will not review or publish articles
based on studies that are conducted under conditions that
allow the sponsor to have sole control of the data or to
withhold publication.”
The editors of The Annals and The Journal have ex-
pressed support for the general thrust of the multi-authored
editorial. They also support a specific policy to consider
rejecting a manuscript describing a study in which an entity
other than the investigator either had sole control of the data
or had veto power over publication. Both The Annals and
The Journal have added new language to their respective
“Information For Authors” pages that reflects this policy
change. The added language states: “Each author must
indicate whether or not he or she has had full ‘Freedom of
Investigation’ before, during, and after this study. ‘Freedom
of Investigation’ is defined as freedom from outside inter-
ests in controlling the design of the study, acquisition of
data, collection, analysis, and interpretation of data, and
having freedom to fully disclose all results.” If the investi-
gators did not have full freedom of investigation, a letter of
explanation will be required, and publication may be denied.
Collaboration between industry and research scientists
has been abundantly fruitful, and university administrations
have put in place systems that accommodate industry-
sponsored research. These have made possible great ad-
vances in the care of thoracic surgical patients. Yet, there
have been occasions when these usually nurturing hands
have challenged the integrity of science. The journal policy
we describe is intended to have two effects. One is to give
investigators powerful support from our specialty’s most
prestigious and largest circulation journals in negotiating
ethically acceptable contracts with industrial sponsors and
in dealing with undue delays imposed by others, such as
intellectual property officers of universities. The second is
to assure that readers of our journals have enough informa-
tion to make informed judgments about potential biases in
research results and their interpretation, with the under-
standing that the authors had control of the data and its
analysis and of the decision to publish. The accuracy of the
information provided to the editors rests upon the long
tradition of expecting that the information requested of
authors will be provided fully and honestly. Journals must be
able to rely on the integrity and honesty of investigators in
providing accurate information to their readers, for these char-
acter traits are the life blood of the entire corpus of cardiotho-
racic research and the clinical practices that depend upon it.
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